- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00992290
Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
Probiotic LGG in Patients With Minimal Hepatic Encephalopathy
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Development of complementary and alternative medicine approaches to liver disease is a priority area at NCCAM. Minimal hepatic encephalopathy (MHE) is a significant complication of cirrhosis which can result in poor quality of life, impaired cognition and difficulty in driving motor vehicles with a high traffic accident risk. MHE is estimated to affect one half of the 5.5 million cirrhotics in the U.S. Despite these negative outcomes, there is no consensus on treatment of MHE. Currently available therapies for MHE act on intestinal flora but are limited by adverse effects (i.e. lactulose-induced diarrhea), which negatively impact adherence. Probiotic bacterial supplements, which also act on intestinal flora, are an emerging therapy for MHE. Our group has performed a pilot, randomized trial which demonstrated a significantly higher rate of MHE reversal with excellent adherence in patients randomized to probiotic yogurt compared to no therapy. This proposal intends to define Lactobacillus GG (LGG) as a biologically-based alternative therapy for MHE with special focus on metabolic and stool bacteriologic changes.
The hypothesis of this Phase I proposal is: LGG will be safe and efficacious for the treatment of minimal hepatic encephalopathy compared to placebo in a randomized, double-blind trial.
This will be carried out with four specific aims:
Specific aim 1: To define the safety and tolerability of LGG in patients with minimal hepatic encephalopathy against placebo in a Phase I randomized controlled trial.
Specific aim 2: To define the effect of LGG on intestinal microflora composition in cirrhotics with minimal hepatic encephalopathy using 16s stool DNA sequencing in a randomized, placebo-controlled trial.
Specific aim 3: To determine the effect of LGG on metabolic biomarkers and cytokines in stool, urine and blood using nuclear magnetic resonance spectroscopy in minimal hepatic encephalopathy.
Specific aim 4: To determine the effect of LGG on psychometric function in patients with minimal hepatic encephalopathy.
The specific aim and sub-aims will be tested in 30 patients with non-alcoholic cirrhosis and MHE: 15 randomized to LGG and 15 randomized to placebo to be taken BID for 8 weeks with detailed psychometric, metabolic, anthropometric and bacteriologic evaluation. Results generated from this study will form the basis for a RO1 proposal to develop the use of probiotics as a biologically-based alternative treatment with long-term outcomes of prognosis, development of overt encephalopathy and prevention of traffic accidents in patients with MHE.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298
- Virginia Commonwealth University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age: 18-65 years
- Histological evidence of cirrhosis
- Maintenance of cirrhosis treatment and stability for 6 months
- Mini-mental state exam score > 25
- Presence of MHE on psychometric testing
Exclusion Criteria:
- Rx for MHE or OHE
- Antibiotics within 6 weeks
- Yogurt consumption within 2 weeks
- Neutrophil count < 500
- Inflammatory bowel disease
- History of pancreatitis
- Hepato-cellular carcinoma
- Recent (6 weeks) gastrointestinal bleed
- Recent (6 months) alcohol intake
- Psychoactive medications (including interferon/antipsychotics)
- Liver transplant
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Placebo
|
1 capsule of lactobacillus GG BID compared to placebo BID
|
Experimentell: Lactobacillus GG
|
1 capsule of lactobacillus GG BID compared to placebo BID
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Safety of LGG
Tidsram: 3 years
|
3 years
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Quality of life measured by sickness impact profile
Tidsram: 3 years
|
3 years
|
Bacteriology measured in the stool flora by specialized non-culture techniques
Tidsram: 3 years
|
3 years
|
Metabonomics and psychometric testing using a standard psychometric battery
Tidsram: 3 years
|
3 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Jasmohan S Bajaj, MD, MSc, Virginia Commonwealth University
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HM12123
- 1U01AT004428-01A1 (U.S.S. NIH-anslag/kontrakt)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Minimal hepatisk encefalopati
-
Algemeen Ziekenhuis Maria MiddelaresAvslutadByte av aortaklaff | Mitralklaffkirurgi | Minimal invasiv hjärtkirurgi | Minimal invasiv direkt kransartärbypassBelgien
-
Universitätsklinikum Hamburg-EppendorfRekryteringSerratus Anterior Plane Block | Minimal invasiv hjärtkirurgi | Minimal invasiv hjärtkirurgi MitralklaffkirurgiTyskland
-
Koç UniversityRekryteringMinimal invasiv hjärtkirurgi | Romboid interkostalt nervblockKalkon
-
Ataturk UniversityAvslutadEfterlevnad, patient | Lungfunktionstest | Minimal Flow Anestesi | Medium Flow Anestesi | Peak Inspiratuar PressureKalkon
-
Assiut UniversityOkändatt utvärdera Letrozol som en modalitet för minimal ovariestimulering i ICSI-cykler.Egypten
-
Winners ClinicAvslutadAnsiktslyft | Upphängningsteknik | Minimal invasiv kirurgiKorea, Republiken av
-
Assistance Publique - Hôpitaux de ParisRekryteringMinimal Change Nephrotic Syndrome (MCNS)Frankrike
-
Astellas Pharma Korea, Inc.AvslutadMinimal Change Nephrotic Syndrome (MCNS) | MCNSKorea, Republiken av
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)IndragenAkut myeloid leukemi | Minimal kvarvarande sjukdomsnegativitetFörenta staterna
-
VIST - Faculty of Applied SciencesRekryteringMinimal erytemdosSlovenien
Kliniska prövningar på Lactobacillus GG
-
National Institute of Pediatrics, MexicoNekutli S.A. de C.V.Avslutad
-
Duke UniversityAvslutadMikrobiomFörenta staterna
-
Tufts Medical CenterAvslutadVankomycinresistent enterokockkoloniseringFörenta staterna
-
Groningen Research Institute for Asthma and COPDNumico Research Wageningen, the NetherlandsAvslutadAtopisk dermatit | Atopiskt eksem | Infantilt eksemNederländerna
-
Federico II UniversityOkändKomjölksallergiItalien
-
Pablo Román LópezAvslutad
-
Shriners Hospitals for ChildrenAvslutad
-
Medical University of WarsawOkändLuftvägsinfektioner | Gastroesofageal refluxsjukdom | Gastrointestinala infektionerPolen
-
Creighton UniversityAvslutadLunginflammation | Ventilatorassocierad lunginflammationFörenta staterna
-
Valio LtdUniversity of Virginia; University of Helsinki; Medcare LtdAvslutad